Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna ExperienceCristina Papayannidis, Giovanni Martinelli, Maria Chiara Abbenante et al.|Blood|2013Cited by 1
Abstract CT312: Ponatinib is well tolerated and active in patients with relapsed/refractory philadelphia positive leukemias: The Bologna experienceCristina Papayannidis, Giovanni Martinelli, Caterina De Benedittis et al.|Cancer Research|2014Cited by 0